MR generic application [Regulatives / Guidelines]

posted by vixen – Czechia, 2020-03-23 19:40 (135 d 12:55 ago) – Posting: # 21296
Views: 1,211

Hi Mikkabel,
More details are needed to determine what we are dealing with here:
- presumably it's an application for Europe?
- is it a single or multiple unit formulation?
- what does the reference SmPC say about intake with/without food?
- is accumulation expected?
- do all three strengths meet the general biowaiver criteria per section 4.1.6 of the Guideline on the investigation of bioequivalence?
- is the shape of all three strengths similar?
- which two strengths represent the extremes? consider it separately for each of the factors listed by section 6.6. of EMA MR Guideline.

Are you familiar with Annex IV to the EMA Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms?


Complete thread:

 Admin contact
20,969 posts in 4,374 threads, 1,461 registered users;
online 13 (0 registered, 13 guests [including 10 identified bots]).
Forum time: Thursday 09:36 CEST (Europe/Vienna)

It is a good morning exercise for a research scientist
to discard a pet hypothesis every day before breakfast.
It keeps him young.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz